Meeting
2019 ASCO Annual Meeting
Activity of venetoclax-based therapy in TP53-mutated acute myeloid leukemia.
Authors
Mahran Shoukier
University of Texas MD Anderson Cancer Center, Houston, TX
Mahran Shoukier , Marina Konopleva , Courtney Denton Dinardo , Farhad Ravandi , Michael Andreeff , Guillermo Garcia-Manero , Elias Jabbour , Naval Guastad Daver , Gautam Borthakur , Naveen Pemmaraju , Guillermo Montalban-Bravo , Christopher Brent Benton , Nicholas James Short , Kapil N. Bhalla , Jorge E. Cortes , Hagop M. Kantarjian , Tapan M. Kadia
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Hematologic Malignancies—Leukemia, Myelodysplastic Syndromes, and Allotransplant
Track
Hematologic Malignancies—Leukemia, Myelodysplastic Syndromes, and Allotransplant
Sub Track
Acute Leukemia
Citation
J Clin Oncol 37, 2019 (suppl; abstr 7034)
DOI
10.1200/JCO.2019.37.15_suppl.7034
Abstract #
7034
Poster Bd #
409
Abstract Disclosures
Similar Posters
Poster
2020 ASCO Virtual Scientific Program
Venetoclax (Ven) added to intensive chemo with cladribine, idarubicin, and AraC (CLIA) achieves high rates of durable complete remission with low rates of measurable residual disease (MRD) in pts with newly diagnosed acute myeloid leukemia (AML).
First Author: Tapan M. Kadia
Poster
2022 ASCO Annual Meeting
Lower-intensity CPX-351 + venetoclax for patients with newly diagnosed AML who are unfit for intensive chemotherapy.
First Author: Geoffrey L. Uy
Poster
2021 ASCO Annual Meeting
Preliminary results of V-FAST, a phase 1b master trial to investigate CPX-351 combined with targeted agents in newly diagnosed AML.
First Author: Vinod Pullarkat
Poster
2018 ASCO Annual Meeting
Management and outcomes of 222 CLL patients (pts) treated with venetoclax (VEN) in the real world.
First Author: Chadi Nabhan